Nkarta Stock (NASDAQ:NKTX)

Forecast Ownership Financials Chart

Previous Close

$2.30

52W Range

$1.70 - $3.72

50D Avg

$2.83

200D Avg

$2.39

Market Cap

$162.41M

Avg Vol (3M)

$716.70K

Beta

0.92

Div Yield

NKTX Company Profile

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

108

IPO Date

Jul 10, 2020

Website

NKTX Performance

NKTX Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-122.00M	$-128.19M	$-131.65M
Net Income	$-104.08M	$-108.79M	$-117.50M
EBITDA	$-122.00M	$-119.04M	$-120.48M
Basic EPS	$-1.41	$-1.60	$-2.40
Diluted EPS	$-1.41	$-1.60	$-2.40

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
MOLN	Molecular Partners AG
ALEC	Alector, Inc.
FATE	Fate Therapeutics, Inc.
VOR	Vor Biopharma Inc.
ELTX	Elicio Therapeutics, Inc.
FBRX	Forte Biosciences, Inc.
PEPG	PepGen Inc.
SAVA	Cassava Sciences, Inc.